Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clearmind Medicine Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces 1-for-10 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC TSX-V:NTLX
News headline image
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND SPRC
News headline image
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND PLRZ
News headline image
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
News headline image
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
From Clearmind Medicine Inc.
Via GlobeNewswire
Tickers CMND
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.